S. Ciummo

发表

CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality

P. Lollini, P. Lanuti, L. Landuzzi, 2022, Journal of Hematology & Oncology.

Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.

M. Bellone, E. Di Carlo, S. Caputo, 2018, Cancer research.

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs

M. Todaro, G. Stassi, P. Lanuti, 2021, Frontiers in Cell and Developmental Biology.

Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival

E. Di Carlo, C. Sorrentino, Luigi D'Antonio, 2021, Frontiers in Immunology.

Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival

M. Marchisio, Li-Fan Lu, P. Lanuti, 2019, Journal of Immunotherapy for Cancer.

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome

M. Todaro, P. Lanuti, A. Turdo, 2021, Journal for ImmunoTherapy of Cancer.

Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival

L. Lotti, E. Di Carlo, C. Sorrentino, 2023, Journal for ImmunoTherapy of Cancer.

Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways

E. Di Carlo, S. Ciummo, Cristiano Fieni, 2023, Journal of Experimental & Clinical Cancer Research.

Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.

E. Di Carlo, Darien Calvo Garcia, S. Ciummo, 2024, Experimental & molecular medicine.

Nanomedicine for cancer patient‐centered care

E. Di Carlo, S. Ciummo, Cristiano Fieni, 2024, MedComm.